Standing in the Gap: Psychedelic Advocacy, Communities of Color, and the Politics of Knowledge Production
T. Reuter, Fanicy Sears, Lisa L. Gezon
Anthropology of Consciousness December 1, 2025 DOI: 10.1111/anoc.70026 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Key findings | Institutional resistance to discussing psychedelic medicine in academic settings reflects knowledge politics and structural power imbalances, highlighting the need for more inclusive and equitable approaches. |
Abstract
Psychedelic research has opened unexpected avenues for advocacy. This paper explores the intersection of advocacy and an ethnographic study on psychedelic integration in the Southeast United States. Mental health professionals aim to make information about the safe use of psychedelics more accessible, even in a legal climate where these substances are illegal and enforcement has historically targeted people of color. This case study examines the challenges of proposing a panel on psychedelic medicine for a university symposium on substance use and social justice. The panel sought to discuss how clinicians and scientists could collaborate with communities to use psychedelic therapies to address addiction and its underlying causes, such as racial trauma, in equitable and community‐centered ways. However, resistance from organizers—due to concerns about the legal status of psychedelics and limited clinical trial data—highlighted the complexities of advocating for such discussions in academic settings. This paper explores how people from diverse communities “stand in the gap” together to challenge structural power imbalances and shift paradigms around these critical issues. It underscores the significance of knowledge politics in university spaces and the risk of tokenism in community‐engaged research, calling for more inclusive, courageous, and equitable approaches to these conversations.
Citations in the library
Cites 42
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology March 1, 2015
and 37 more in the library